AtzpodienJ., KörferA., FranksC.R., PoliwodaH., KirchnerH.Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies.Lancet1990; I: 1509–12.
2.
AtzpodienJ., KirchnerH.Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.Klin Wochenschr1990; 68: 1–11.
3.
LissoniP., BarniS., ArdizzoiaA.Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha 2.Eur J Cancer, in press.
4.
GemloB.T., PalladinoM.A., JaffeH.S., EspevikT.P., RaynerA.A.Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells.Cancer Res1988; 48: 5864–7.
5.
LissoniP., TisiE., BrivioF.Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.Eur J Cancer1991; 27: 1014–6.
NelsonD.L., RubinL.A., KurmanC.C., FritzM.E., BoutinB.An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro.J Clin Immunol1986; 6: 114–20.
9.
LissoniP., PittalisS., BrivioF.IL-3 effect on monocyte-mediated stimulation of soluble IL-2 receptor (SIL-2R) release from lymphocytes.Eur J Cancer1991; Suppl 2: 1371.
